Compare Amphastar Pharmaceuticals Inc (AMPH) vs Annaly Capital Management, Inc. (NLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Annaly Capital Management, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.3 (market cap $826.08M), while Annaly Capital Management, Inc. trades at $22.77 (market cap $16.75B). The key difference: Annaly Capital Management, Inc. is far larger — about 20.3× Amphastar Pharmaceuticals Inc's market cap, and Annaly Capital Management, Inc. pays a 13.12% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | NLY | |
|---|---|---|
Market Cap | $826.08M | $16.75B |
Sector | Health | Financials |
52-Week High | $30.81 | $24.40 |
52-Week Low | $16.87 | $19.47 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 13.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Annaly Capital Management (NLY) trades at $22.86, up 0.57% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 91.17% net income margin and 15.61% ROE, supported by a recent dividend increase to $0.75 per share. Analyst consensus is bullish with a $24.40 price target, reflecting confidence in its mortgage REIT model amid evolving Fed policy.
NLY offers a high-yield opportunity with manageable risks from interest rate sensitivity. The stock's attractive valuation (P/E 7.37, P/B 1.16) and positive cash flow trends support upside potential, though investors must monitor leverage and macroeconomic shifts that impact mortgage spreads and refinancing activity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Annaly Capital Management, Inc.
Annaly Capital Management Inc is an American mortgage real estate investment trust. The company segments its operations into Residential and Commercial real estate investments. While Annaly's Residential assets are primarily comprised of agency mortgage-backed securities and debentures, it is primarily invested in commercial mortgage loans and mortgage-backed securities in its Commercial unit through its subsidiary, Annaly Commercial Real Estate Group. Agency mortgage-backed securities and debentures make up the majority of the company's overall portfolio. Most of the company's counterparties are located in the U.S. Annaly generates nearly all of its revenue from the spread between interest earned on its assets and interest payments made on its borrowings.
Read more on NLY →
